Expertise in
15
conditions

Dr. David E. Kanamori

Hematology
6501 Truxtun Ave, 
Bakersfield, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral may be required
Before you request
Expertise in
15
conditions
6501 Truxtun Ave, 
Bakersfield, CA 

Overview

David Kanamori is a Hematologist practicing medicine in Bakersfield, California.

Dr. Kanamori is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Anemia, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Dr. Kanamori is board certified in Internal Medicine (Sub: Medical Oncology), Internal Medicine (Sub: Hematology), and Internal Medicine. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 10 clinical trials. Dr. Kanamori is currently accepting new patients.

Specialties

Hematology

Licenses

Specialist in CA

Board Certifications

Internal Medicine (Sub: Medical Oncology)
Internal Medicine (Sub: Hematology)
Internal Medicine

Fellowships

Medical College of Virginia

Hospital Affiliations

Dignity Health – Memorial Hospital
Bakersfield Memorial Hospital
Adventist Health Tehachapi Valley
Adventist Health Bakersfield

Languages Spoken

English
Filipino
French
Gujarati 
Hindi
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Ravi Patel, M.D., Inc.
6501 Truxtun Ave, Bakersfield, CA 93309

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Terminated
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drugs: Talazoparib, Temozolomide
Study Phase: Phase 2
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
View 9 Less Clinical Trials

1 Total Publications

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Journal: Anti-cancer drugs
Published: March 16, 2019
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

Ravi Patel, M.D., Inc.

6501 Truxtun Ave, 
Bakersfield, CA 
 (0.1 miles away)
661-322-2206
Languages Spoken:
English, Filipino, French, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients

Shawn Shambaugh is a Hematologist practicing medicine in Bakersfield, California. Dr. Shambaugh is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Anemia, Leukocytosis, and Congenital Hemolytic Anemia. Dr. Shambaugh is currently accepting new patients.

Expertise in
5
conditions
Expertise in
5
conditions
Referral may be required

Adventist Health AIS Cancer Center Pharm

2620 Chester Ave, 
Bakersfield, CA 
 (3.6 miles away)
661-395-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ricardo Salas is a Hematologist practicing medicine in Bakersfield, California. Dr. Salas is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Muscle Invasive Bladder Cancer, and Diffuse Large B-Cell Lymphoma (DLBCL).

Expertise in
5
conditions
Expertise in
5
conditions
Referral may be required
Before you request

Bakersfield Hematology Oncology, Inc.

9800 Brimhall Rd, 
Bakersfield, CA 
 (2.1 miles away)
661-863-9988
Languages Spoken:
English, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Vinh-linh Nguyen is a Hematologist practicing medicine in Bakersfield, California. Dr. Nguyen is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, and Thrombocytopenia. Dr. Nguyen is currently accepting new patients.

Frequently Asked Questions about Dr. David E. Kanamori

How do I make an appointment with Dr. David E. Kanamori?

You can book an appointment with Dr. David E. Kanamori by calling their office at 661-322-2206. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David E. Kanamori a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David E. Kanamori is classified as an Distinguished expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David E. Kanamori specialize in?

While Dr. David E. Kanamori is a Hematology, they have specific expertise in Thrombocytopenia, Anemia, and Congenital Hemolytic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. David E. Kanamori participate in research or clinical trials?

Yes. Dr. David E. Kanamori has published 1 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. David E. Kanamori's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David E. Kanamori accept my insurance?

Dr. David E. Kanamori accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 661-322-2206 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kanamori's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile